Understanding how CBF-1 affects HIV in brain cells
CBF-1 role in regulating HIV reservoir in microglial cells
This study is looking at how a protein called CBF-1 affects HIV hiding in brain immune cells, which could help us find new ways to treat HIV-related brain issues for people living with the virus.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10626867 on NIH RePORTER |
What this research studies
This research investigates the role of CBF-1 in regulating HIV reservoirs specifically in microglial cells, which are immune cells in the brain. The study aims to uncover the molecular mechanisms that allow HIV to persist in these cells, contributing to complications such as HIV-associated neurocognitive disorder. By analyzing how CBF-1 influences HIV latency in microglial cells, the researchers hope to identify potential therapeutic targets that could help manage HIV in the central nervous system. This work is crucial as it addresses a significant gap in our understanding of HIV persistence beyond the well-studied CD4+ T cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV, particularly those experiencing cognitive issues related to the virus.
Not a fit: Patients who are not living with HIV or those who do not have any neurological complications related to HIV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for reducing HIV reservoirs in the brain, potentially improving cognitive health in HIV patients.
How similar studies have performed: While research on HIV latency in lymphoid cells is well-established, the focus on microglial cells and the role of CBF-1 is relatively novel and has not been extensively tested.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Tyagi, Mudit — Thomas Jefferson University
- Study coordinator: Tyagi, Mudit
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.